Assessing and accessing the small airways; implications for asthma management

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2013, Pages 172-179

  Scichilone, Nicola ^a   Contoli, Marco ^b   Paleari, Davide ^c   Pirina, Pietro ^d   Rossi, Andrea ^e   Sanguinetti, Claudio Maria ^f   Santus, Pierachille ^g   Sofia, Matteo ^h   Sverzellati, Nicola ⁱ  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d UOC di Radiologia   (Italy)

^e MAGGIORE HOSPITAL   (Italy)

^f Quisisana Clinical Center   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h MONALDI HOSPITAL   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Asthma; Extrafine; Imaging; Inflammation; Peripheral airways; Small airways

Indexed keywords

BECLOMETASONE; CICLESONIDE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; NITROUS OXIDE;

AIRWAY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DENSITY; EOSINOPHIL; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; LUNG VENTILATION; METERED DOSE INHALER; NITROGEN WASHOUT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSCILLOMETRY; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RESIDUAL VOLUME; RESPIRATORY TRACT INFLAMMATION; SINGLE BREATH NITROGEN TEST; SPIROMETRY; VITAL CAPACITY;

ASTHMA; BREATH TESTS; FORCED EXPIRATORY VOLUME; HUMANS; NITRIC OXIDE; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84874569220     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.10.001     Document Type: Article

References (83)

1. Aubier M., Neukirch F., Annesi-Maesano I. Epidemiology of asthma and allergies. The prevalence of allergies increases worldwide, and asthma has reached his highest-ever prevalence in Europe: why?. Bull Acad Natl Med 2005, 189(7):1419-1434. discussion 1434.
2. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention 2011, [online]. Available from URL:, [Accessed 19.11.10]. http://www.ginasthma.com.
3. Ulrik C.S., Lange P. Targeting small airways in asthma: improvement in clinical benefit?. Clin Respir J 2011, 5(3):125-130.
4. Martin R.J. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002, 109(Suppl.):S447-S460.
5. National Heart Blood and Lung Institute. National asthma education and prevention program. Expert Panel Report 3 (EPR3): guidelines for the diagnosis and management of asthma [online]. Available at: URL: [Accessed 02.03.11]. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.
6. British Thoracic Society. British guideline on the management of asthma: a national clinical guideline (revised 2009) [online]. Available from URL: [Accessed 19.11.10]. http://www.brit-thoracic.org.uk.
7. Contoli M., Bousquet J., Fabbri L.M., Magnussen H., Rabe K.F., Siafakas N.M., et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy 2010, 125:830-837.
8. Scichilone N., Battaglia S., Olivieri D., Bellia V. The role of small airways in monitoring the response to asthma treatment: what is beyond FEV1?. Allergy 2009, 64(11):1563-1569.
9. Tulic M.K., Christodoulopoulos P., Hamid Q. Small airway inflammation in asthma. Respir Res 2001, 2:333-339.
10. Carroll N., Cooke C., James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997 Feb, 10(2):292-300.
11. Hamid Q., Song Y., Kotsimbos T.C., Minshall E., Bai T.R., Hegele R.G., et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997, 100(1):44-51.
12. Wenzel S.E., Szefler S.J., Leung D.Y., Sloan S.I., Rex M.D., Martin R.J. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997 Sep, 156(3 Pt 1):737-743.
13. Mauad T., Silva L.F., Santos M.A., Grinberg L., Bernardi F.D., Martins M.A., et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004, 170(8):857-862.
14. Contoli M., Kraft M., Hamid Q., Bousquet J., Rabe K.F., Fabbri L.M., et al. Do small airway abnormalities characterize asthma phenotypes? In search of proof. Clin Exp Allergy 2012 Aug, 42(8):1150-1160.
15. Kraft M. Part III: location of asthma inflammation and the distal airways: clinical implications. Curr Med Res Opin 2007, 23(Suppl. 3):S21-S27.
16. Balzar S., Wenzel S.E., Chu H.W. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 2002, 20(2):254-259.
17. Tashkin D.P. The role of small airway inflammation in asthma. Allergy Asthma Proc 2002, 23(4):233-242.
18. Hamid Q.A. Peripheral inflammation is more important than central inflammation. Respir Med 1997, 91(Suppl. A):11-12.
19. Carroll N.G., Mutavdzic S., James A.L. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002, 19(5):879-885.
20. Berry M., Hargadon B., Morgan A., Shelley M., Richter J., Shaw D., et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005, 25(6):986-991.
21. Benayoun L., Druilhe A., Dombret M.C., Aubier M., Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003, 167(10):1360-1368.
22. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005, 172(2):149-160.
23. Kraft M., Pak J., Martin R.J., Kaminsky D., Irvin C.G. Distal lung dysfunction at night in nocturnal asthma. Am J Respir Crit Care Med 2001, 163(7):1551-1556.
24. Kraft M., Martin R.J., Wilson S., Djukanovic R., Holgate S.T. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999, 159(1):228-234.
25. Irvin C.G., Pak J., Martin R.J. Airway-parenchyma uncoupling in nocturnal asthma. Am J Respir Crit Care Med 2000, 161(1):50-56.
26. Enright P.L., Lebowitz M.D., Cockroft D.W. Physiologic measures: pulmonary function tests. Asthma outcome. Am J Respir Crit Care Med 1994, 149(2 Pt 2):S9-S18. discussion S19-20.
27. Ruppel G.L., Enright P.L. Pulmonary function testing. Respir Care 2012, 57(1):165-175.
28. Stânescu D. Small airways obstruction syndrome. Chest 1999, 116(1):231-233.
29. Halbert R.J., Natoli J.L., Gano A., Badamgarav E., Buist A.S., Mannino D.M. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006, 28:523-532.
30. Timmins S., Diba C., Farrow C., Shoeffel R., Berend N., Salome C., et al. The relationship between airflow obstruction, emphysema extent and small airways function in COPD. Chest 2012, 142(2):312-319.
31. Pellegrino R., Viegi G., Brusasco V., Crapo R.O., Burgos F., Casaburi R., et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26(5):948-968.
32. Sorkness R.L., Bleecker E.R., Busse W.W., Calhoun W.J., Castro M., Chung K.F., et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J. Appl. Phys. 2008, 104:394-403.
33. Dubois A.B., Brody A.W., Lewis D.H., Burgess B.F. Oscillation mechanics of lungs and chest in man. J Appl Physiol 1956, 8:587-594.
34. Marotta A., Klinnert M.D., Price M.R., Larsen G.L., Liu A.H. J Allergy Clin Immunol 2003, 112:317-322.
35. Smith H.J., Reinhold P., Goldman M.D. Forced oscillation technique and impulse oscillometry. Lung function testing: European respiratory society monograph 2005, vol. 31. [Chapter 5], European Respiratory Society, Sheffield, UK.
36. Nève V., Edmé J.L., Devos P., Deschildre A., Thumerelle C., Santos C., et al. Spirometry in 3-5-year-old children with asthma. Pediatr Pulmonol 2006 Aug, 41(8):735-743.
37. Takeda T., Oga T., Niimi A., Matsumoto H., Ito I., Yamaguchi M., et al. Relationship between small airway function and health status, dyspnea and disease control in asthma. Respiration 2010, 80(2):120-126.
38. Winkler J., Hagert-Winkler A., Wirtz H., Schauer J., Kahn T., Hoheisel G. Impulse oscillometry in the diagnosis of the severity of obstructive pulmonary disease. Pneumologie 2009, 63(5):266-275.
39. Oppenheimer B.W., Goldring R.M., Berger K.I. Distal airway function assessed by oscillometry at varying respiratory rate: comparison with dynamic compliance. COPD 2009 Jun, 6(3):162-170.
40. Drummond G.B., Milic-Emili J. Forty years of closing volume. Br J Anaesth 2007, 99(6):772-774.
41. Buist A.S. Current status of small airways disease. Chest 1984, 86(1):100-105.
42. van Veen I.H., Sterk P.J., Schot R., Gauw S.A., Rabe K.F., Bel E.H. Eur Respir J 2006 May, 27(5):951-956.
43. Dutrieue B., Vanholsbeeck F., Verbanck S., Paiva M. A human acinar structure for simulation of realistic alveolar plateau slopes. J Appl Physiol 2000, 89(5):1859-1867.
44. Verbanck S., Schuermans D., van Muylem A., Melot C., Noppen M., Vincken W., et al. Conductive and acinar lung-zone contributions to ventilation inhomogeneity in COPD. Am J Respir Crit Care Med 1998, 157:1573-1577.
45. Verbanck S., Schuermans D., Paiva M., Vincken W. The functional benefit of anti-inflammatory aerosols in the lung periphery. J Allergy Clin Immunol 2006, 118(2):340-346.
46. Verbanck S., Schuermans D., Van Muylem A., Paiva M., Noppen M., Vincken W. Ventilation distribution during histamine provocation. J Appl Physiol 1997, 83(6):1907-1916.
47. Verbanck S., Thompson B.R., Schuermans D., Kalsi H., Biddiscombe M., Stuart-Andrews C., et al. Ventilation heterogeneity in the acinar and conductive zones of the normal ageing lung. Thorax 2012 Sep, 67(9):789-795.
48. Peslin R., Navajas D., Rotger M., Farré R. Validity of the esophageal balloon technique at high frequencies. J Appl Physiol 1993, 74(3):1039-1044.
49. Ingram R.H., Schilder D.P. Association of decrease in dynamic compliance with a change in gas distribution. J Appl Physiol 1967, 23:911.
50. Fowler W.S. Lung function studies. III. Uneven pulmonary ventilation in normal subjects and in patients with pulmonary disease. J Appl Physiol 1949, 2:283.
51. Buist A.S., Ross B.B. Quantitative analysis of the alveolar plateau in the diagnosis of early obstruction. Am Rev Respir Dis 1973, 108:1078.
52. Barnes P.J., Dweik R.A., Gelb A.F., Gibson P.G., George S.C., Grasemann H., et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010, 138(3):682-692.
53. Stern G., de Jongste J., van der Valk R., Baraldi E., Carraro S., Thamrin C., et al. Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. J Allergy Clin Immunol 2011, 128(2):293-300.
54. Horváth I., Hunt J., Barnes P.J., Alving K., Antczak A., Baraldi E., ATS/ERS Task Force on Exhaled Breath Condensate, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005, 26(3):523-548.
55. Battaglia S., den Hertog H., Timmers M.C., Lazeroms S.P., Vignola A.M., Rabe K.F., et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005, 60(8):639-644.
56. Sofia M., Maniscalco M., de Laurentiis G., Paris D., Melck D., Motta A. Exploring airway diseases by NMR-based metabonomics: a review of application to exhaled breath condensate. J Biomed Biotechnol 2011, 403260.
57. Carraro S., Rezzi S., Reniero F., Héberger K., Giordano G., Zanconato S., et al. Metabolomics applied to exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2007, 175(10):986-990.
58. Gono H., Fujimoto K., Kawakami S., Kubo K. Evaluation of airway wall thickness and air trapping by HRCT in asymptomatic asthma. Eur Respir J 2003, 22:965-971.
59. Laurent F., Latrabe V., Raherison C., Marthan R., Tunon-de-Lara J.M. Functional significance of air trapping detected in moderate asthma. Eur Radiol 2000, 10:1404-1410.
60. Newman K.B., Lynch D.A., Newman L.S., Ellegood D., Newell J.D. Quantitative computed tomography detects air trapping due to asthma. Chest 1994, 106:105-109.
61. Beigelman-Aubry C., Capderou A., Grenier P.A., Straus C., Becquemin M.H., Similowski T., et al. Mild intermittent asthma: CT assessment of bronchial cross-sectional area and lung attenuation at controlled lung volume. Radiology 2002, 223:181-187.
62. Goldin J.G., Tashkin D.P., Kleerup E.C., Greaser L.E., Haywood U.M., Sayre J.W., et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999, 104:S258-S267.
63. Jain N., Covar R.A., Gleason M.C., Newell J.D., Gelfand E.W., Spahn J.D. Quantitative computed tomography detects peripheral airway disease in asthmatic children. Pediatr Pulmonol 2005, 40(3):211-218.
64. Busacker A., Newell J.D., Keefe T., Hoffman E.A., Granroth J.C., Castro M., et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009, 135(1):48-56.
65. Tunon-de-Lara J.M., Laurent F., Giraud V., Perez T., Aguilaniu B., Meziane H., et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J Allergy Clin Immunol 2007, 119:583-590.
66. Montaudon M., Lederlin M., Reich S., Begueret H., Tunon-de-Lara JM., Marthan R., et al. Bronchial measurements in patients with asthma: comparison of quantitative thin-section CT findings with those in healthy subjects and correlation with pathologic findings. Radiology 2009, 253:844-853.
67. Chrystyn H., Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Resp J 2009, 18(4):243-249.
68. Laube B.L., Janssens H.M., de Jongh F.H., Devadason S.G., Dhand R., Diot P., European Respiratory Society; International Society for Aerosols in Medicine, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011, 37(6):1308-1331.
69. Fabbri L.M., Nicolini G., Olivieri D., Papi A. Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother 2008, 9(3):479-490.
70. Nicolini G., Scichilone N., Bizzi A., Papi A., Fabbri L.M. Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations. Ther Clin Risk Manag 2008, 4(5):855-864.
71. Hauber H., Taha R., Bergeron C., Migounov V., Hamid Q., Olivenstein R. Effects of hydrofluoroalkane and dry powder-formulated corticosteroids on sputum inflammatory markers in asthmatic patients. Can Respir J 2006, 13:73-78.
72. Busse W.W., Brazinsky S., Jacobson K., Stricker W., Schmitt K., Vanden Burgt J., et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999, 104:1215-1222.
73. Juniper E.F., Price D.B., Stampone P.A., Creemers J.P.H.M., Mol S.J.M., Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002, 121:1824-1832.
74. Huchon G., Magnussen H., Chuchalin A., Dymek L., Gonod F.B., Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009, 103:41-49.
75. Papi A., Paggiaro P., Nicolini G., Vignola A.M., Fabbri L.M. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007, 62:1182-1188.
76. Papi A., Paggiaro P.L., Nicolini G., Vignola A.M., Fabbri L.M. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007, 29:682-689.
77. Müller V., Gálffy G., Eszes N., Losonczy G., Bizzi A., Nicolini G., et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. BMC Pulm Med 2011, 11:40.
78. Allegra L., Cremonesi G., Girbino G., Ingrassia E., Marsico S., Nicolini G., PRISMA (PRospectIve Study on asthMA control) Study Group, et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med 2012, 106(2):205-214.
79. Scichilone N., Battaglia S., Sorino C., Paglino G., Martino L., Paterno A., et al. Effects of extra-fine inhaled beclomethasone/formoterol on large and small airways in asthma. Allergy 2010, 65(7):897-902.
80. Leach C.L., Kuehl P.J., Chand R., Ketai L., Norenberg J.P., McDonald J.D. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol 2012 Mar, 108(3):195-200.
81. Hozawa S., Terada M., Hozawa M. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. Pulm Pharmacol Ther 2011 Oct, 24(5):571-576.
82. De Backer W. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010 Jun, 23(3):137-148.
83. Kleinstreuer C., Zhang Z. Airflow and particle transport in the human respiratory system. Ann Rev Fluid Mechanics 2010, 42:301-334.